Amylin

San Diego, United States Founded: 1987 • Age: 39 yrs Acquired By Bristol-Myers Squibb
Peptide hormone analogues to treat metabolic diseases
Request Access

About Amylin

Amylin is a company based in San Diego (United States) founded in 1987 was acquired by Bristol-Myers Squibb in June 2012.. Amylin operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.

  • Headquarter San Diego, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Amylin Pharmaceuticals Llc
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $100 M (USD), Post-IPO

    Feb 22, 2000

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Bristol-Myers Squibb

    (Jun 29, 2012)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Amylin

  • Total Funding
  • Total Rounds 1
  • Last Round Post-IPO — $100.0M
  • First Round

    (22 Feb 2000)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2000 Amount Post-IPO - Amylin Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Amylin

Amylin has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Amylin

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Amylin

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Amylin Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Amylin

Amylin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
domain founded_year HQ Location
Developer of small-molecule drugs
domain founded_year HQ Location
Biologics are developed for cardio-metabolic and liver diseases.
domain founded_year HQ Location
Developer of cortisol modulators for the treatment of various diseases
domain founded_year HQ Location
Cell therapy for diabetes is developed from stem cells.
domain founded_year HQ Location
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Amylin

Frequently Asked Questions about Amylin

When was Amylin founded?

Amylin was founded in 1987 and raised its 1st funding round 13 years after it was founded.

Where is Amylin located?

Amylin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

What does Amylin do?

Amylin Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDAapproved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystroph. In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for 5.3 billion. In December 2013, Amylin was acquired by AstraZeneca.

Who are the top competitors of Amylin?

Amylin's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.

Who are Amylin's investors?

Amylin has 1 investor. Key investors include Bristol-Myers Squibb.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available